凯赛生物(688065) - 2025 Q4 - 年度业绩

Financial Performance - In 2025, the company achieved operating revenue of CNY 329,544.89 million, an increase of 11.41% year-on-year[4] - The total profit for 2025 was CNY 63,150.35 million, reflecting a year-on-year growth of 15.23%[4] - Net profit attributable to shareholders reached CNY 56,572.04 million, up 15.70% compared to the previous year[4] - The net profit after deducting non-recurring gains and losses was CNY 52,592.04 million, an increase of 13.17% year-on-year[4] - The company experienced significant growth in its main business, leading to increased sales revenue and gross profit[4] - The net profit, after excluding the impact of exchange rate fluctuations, increased by 37.13% year-on-year[4] Assets and Equity - Total assets at the end of 2025 amounted to CNY 2,389,970.19 million, a growth of 25.65% from the beginning of the year[4] - Net assets attributable to shareholders increased by 53.86% year-on-year, totaling CNY 1,770,496.77 million, primarily due to the issuance of 138 million A-shares raising CNY 59.15 billion[5] Earnings and Returns - Basic earnings per share were CNY 0.83, a decrease of 1.19% compared to the previous year[4] - The weighted average return on net assets was 3.52%, down 0.79 percentage points year-on-year[4]